At the news
? BULLISHIMPACT 7/10 6-K filed Sep 14, 2026 at 06:25 ET
Takeda announced FDA Priority Review acceptance of its NDA for zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis, with a PDUFA target in Q1 2027. Phase 3 data showed strong efficacy across endpoints (e.g., ~70% sPGA 0/1 at week 16) with a clean safety profile, positioning it as a potential best-in-class oral TYK2 inhibitor. The EMA also accepted the MAA, and the filing has no impact on FY2027 guidance, making this a significant pipeline catalyst but with binary regulatory risk ahead.
- FDA accepted NDA under Priority Review for zasocitinib (TAK-279) in moderate-to-severe plaque psoriasis.
- PDUFA target action date is Q1 2027.
- Phase 3 LATITUDE PsO 3001/3002 studies met all co-primary and 44 ranked secondary endpoints (p<0.001).
- At week 16, 71% (3001) and 69% (3002) of zasocitinib patients achieved sPGA 0/1 vs 11%/13% placebo.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access